Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nicotine administration reduces striatal MPP+ levels in mice.

M Quik1, D A Di Monte

  • 1The Parkinson's Institute, 1170 Morse Ave., Sunnyvale, CA 94089, USA. mquik@parkinsoninstitute.org

Brain Research
|October 20, 2001
PubMed
Summary

Nicotine reduces striatal 1-methyl-4-phenylpyridinium (MPP+) levels, offering neuroprotection against Parkinson

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.

British journal of haematology·2025
Same author

The striatal cholinergic system in L-dopa-induced dyskinesias.

Journal of neural transmission (Vienna, Austria : 1996)·2018
Same author

Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.

Neuroscience·2015
Same author

Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation.

Cell death & disease·2014
Same author

Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra.

Cell death & disease·2012
Same author

Monoclonal antibodies against ?-bungarotoxin.

Neurochemistry international·2010

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurodegenerative Diseases

Background:

  • Nicotine is known to protect against nigrostriatal damage in Parkinson's disease models.
  • The mechanism by which nicotine exerts neuroprotection is not fully understood.

Purpose of the Study:

  • To investigate if nicotine alters striatal levels of 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of MPTP.
  • To explore the role of MPP+ levels in nicotine's neuroprotective effects.

Main Methods:

  • Mice were administered nicotine prior to and after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injection.
  • Striatal MPP+ levels were measured at various time points post-MPTP administration.
  • The effect of age on nicotine's impact on MPP+ levels was examined.

Main Results:

  • Nicotine administration significantly reduced striatal MPP+ levels in a time-dependent manner.
  • This reduction in MPP+ was more pronounced in older mice compared to younger mice.
  • Nicotine's neuroprotective effect may be linked to its ability to decrease striatal MPP+.

Conclusions:

  • Nicotine's neuroprotective action in MPTP-induced Parkinson's disease models is, at least partly, mediated by reducing striatal MPP+ levels.
  • Age influences the efficacy of nicotine in modulating MPP+ levels, potentially explaining variability in research findings.

Related Experiment Videos